These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 8290969

  • 1. Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
    Lambertenghi Deliliers G, Annaloro C, Oriani A, Pozzoli E, Cortelezzi A, Cortellaro M, Mozzana R, Della Volpe A, Soligo D, Cofrancesco E.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):27-33. PubMed ID: 8290969
    [Abstract] [Full Text] [Related]

  • 2. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
    Deliliers GL, Annaloro C, Oriani A, Della Volpe A, Boschetti C, Cortelezzi A, Maiolo AT.
    Ann Ital Med Int; 1998 Dec; 13(3):146-51. PubMed ID: 9859570
    [Abstract] [Full Text] [Related]

  • 3. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F, Fernández-Barbieri MA, Santarelli MT, Matus-Ridley M, Rosso A, Negri-Aranguren P, Cerutti I, Gomel M, Kvicala R.
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH.
    N Engl J Med; 1998 Dec 03; 339(23):1649-56. PubMed ID: 9834301
    [Abstract] [Full Text] [Related]

  • 5. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 03; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
    Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.
    Br J Haematol; 2005 Oct 03; 131(2):172-9. PubMed ID: 16197446
    [Abstract] [Full Text] [Related]

  • 11. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ, Gallant G, Williams GJ, Woloschuk D, Shore TB, Rubinger M, Schacter BA.
    Cancer; 1998 Oct 01; 83(7):1344-54. PubMed ID: 9762935
    [Abstract] [Full Text] [Related]

  • 12. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Oct 01; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 13. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N, Thomas V, Abrahams L, du Toit C, McDonald A.
    Am J Hematol; 2004 Aug 01; 76(4):319-29. PubMed ID: 15282663
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
    Masaoka T, Ogawa M, Yamada K, Kimura K, Ohhashi Y.
    Gan To Kagaku Ryoho; 1993 Oct 01; 20(13):1995-2005. PubMed ID: 8215474
    [Abstract] [Full Text] [Related]

  • 19. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E, CETLAM AML-99.
    Haematologica; 2004 Jul 01; 89(7):791-800. PubMed ID: 15257930
    [Abstract] [Full Text] [Related]

  • 20. Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience.
    Rassam SM, Turker A, Powles RL, Smith AG, Newland AC, Erskine JG, Pearce RM, Goldstone AH.
    Semin Oncol; 1993 Dec 01; 20(6 Suppl 8):13-9. PubMed ID: 8290967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.